Clinical trials: Monoclonal
Plasma Cell Myeloma Refractory
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult…
- Trial name
- SubQSA (NCT06356571)
- Testing
- Isatuximab SC-OBDS, Montelukast, Dexamethasone
- Where
- 34 sites in United States
- Volunteers
- 64 people
- Sponsor
- Sanofi
Chronic Inflammatory Demyelinating Polyneuropathy
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This is a multi-center, randomized, quadruple-blind, placebo-controlled study to evaluate the efficacy and safety of batoclimab in adult participants with active CIDP.
- Trial name
- NCT05581199
- Testing
- Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly
- Where
- 98 sites in United States, Argentina and 19 more
- Volunteers
- 94 people
- Sponsor
- Immunovant Sciences GmbH
Advanced Solid Tumor, Solid Tumor
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors.
- Trial name
- NCT05981703
- Testing
- BGB-26808, Tislelizumab, Chemotherapy
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 337 people
- Sponsor
- BeOne Medicines
Multiple Sclerosis
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
The purpose of the study is to evaluate the effectiveness and safety of CNTO 1275 in patients with Multiple Sclerosis
- Trial name
- NCT00207727
- Testing
- CNTO 1275
- Volunteers
- 249 people
- Sponsor
- Centocor, Inc.
Crohn's Disease
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
The primary objective of this study is to establish the safety and tolerability of multiple ascending doses (MAD) of foralumab enteric coated capsules administered orally, once daily for 5 days per week over 2 weeks in…
- Trial name
- NCT05028946
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Lymphoma
First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα.
- Trial name
- NCT05737628
- Testing
- BYON4228 + Rituximab
- Where
- 12 sites in Italy, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- Byondis B.V.
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)
An open-label, multicenter study to evaluate the safety and immunogenicity of inactivated VZV vaccine (V212) in participants with hematologic malignancies (HM) who are currently receiving anti-CD20 monoclonal antibodies.
- Trial name
- NCT01460719
- Testing
- V212
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Myasthenia Gravis
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC)…
- Trial name
- NCT05403541
- Testing
- Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Batoclimab 340 mg SC bi-weekly
- Where
- 93 sites in United States, Argentina and 14 more
- Volunteers
- 233 people
- Sponsor
- Immunovant Sciences GmbH
COVID-19
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
- Trial name
- STORM CHASER (NCT04625972)
- Testing
- AZD7442
- Where
- 57 sites in United States, United Kingdom
- Volunteers
- 1,131 people
- Sponsor
- AstraZeneca
Multiple Myeloma
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma (MM).
- Trial name
- NCT00315757
- Testing
- Mapatumumab, Bortezomib
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 105 people
- Sponsor
- Human Genome Sciences Inc.
Systemic Lupus Erythematosus
Saphnelo Use in Females of Child-bearing Potential
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by substantial clinical burden-including organ damage, increased morbidity, and mortality-that often presents in young adulthood and…
- Trial name
- PRIMULA DUS (NCT07431775)
- Testing
- Anifrolumab
- Volunteers
- 26,000,000 people
- Sponsor
- AstraZeneca
NAFLD
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.
- Trial name
- NCT03261739
- Testing
- RYI-018
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 84 people
- Sponsor
- Bird Rock Bio, Inc.
Metastatic Colorectal Cancer
Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-EGFR Monoclonal antibody（SCT200）in patients with wild-type RAS and BRAF mCRC treated with fluorouracil, oxaliplatin and irinotecan after failure…
- Trial name
- NCT03405272
- Testing
- Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
- Where
- 21 sites in China
- Volunteers
- 110 people
- Sponsor
- Sinocelltech Ltd.
Head and Neck Neoplasms
Zalutumumab in Head and Neck Cancer
The purpose of this trial is to determine the safety of zalutumumab as a treatment for head and neck cancer.
- Trial name
- NCT00093041
- Testing
- Zalutumumab
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 28 people
- Sponsor
- Genmab
Advanced Solid Tumor
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and…
- Trial name
- NCT04649385
- Testing
- BGB-15025, Tislelizumab, Carboplatin
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 157 people
- Sponsor
- BeiGene
Rheumatoid Arthritis
Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab
The study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance.
- Trial name
- PROWD (NCT00650390)
- Testing
- adalimumab
- Sponsor
- Abbott
Contraception
An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film
This is an early Phase 1 study to establish proof-of-concept by determining whether an intravaginal film containing a human contraceptive antibody (ZB-06) shows promise to provide contraceptive efficacy using the post-coital…
- Trial name
- NCT04731818
- Testing
- ZB-06
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- KBio Inc
Motavizumab Administration for a Second Season for RSV Prophylaxis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children
The primary objective of this study was to determine the effect on immune reactivity to motavizumab (MEDI-524) of monthly intramuscular (IM) doses of motavizumab (MEDI-524) administered for a second season in children.
- Trial name
- NCT00113490
- Testing
- motavizumab (MEDI-524), palivizumab 15 mg/kg
- Where
- 6 sites in Brazil, Chile
- Volunteers
- 136 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumor
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in…
- Trial name
- NCT05007782
- Testing
- Denikitug, Zimberelimab
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 304 people
- Sponsor
- Gilead Sciences
Broad Solid Tumor
A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with…
- Trial name
- NCT02913313
- Testing
- BMS-986207, Nivolumab, Ipilimumab
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 101 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.